Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints. 

Topic Coronavirus clinical-trials research

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus vaccines Sales Earnings

Medtech Insight: 世界の医療機器・医療技術の最新情報

FDA Boosts Development Of OTC COVID-19 Tests With New Template

A new template from the US FDA explains what information the agency wants to see in regulating COVID-19 tests to be performed outside the laboratory environment.

Topic Coronavirus FDA Diagnostics

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Patient-Reported Data In COVID-Impacted Trials: US FDA Cautions Against Missing Data, Potential Bias

Considerations for switching from in-person to remote collection of patient- and observer-reported outcomes addressed in latest update to Q&A guidance, which also discusses Part 11 compliance requirements in the context of the pandemic and electronic collection of informed consent through MyStudies app.

Topic Coronavirus clinical-trials

Generics Bulletin: ジェネリック＆バイオシミラーニュース

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Topic Coronavirus Distribution

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

Topic Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Remdesivir Compulsory Licensing Is A Dead End For Europe

In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

Topic Coronavirus Intellectual Property policy-and-regulation

awareness, thought-leadership, Scrip: 世界の医療用医...

Scrip Asia 100: Sponsorship Opportunities

The annual “Scrip Asia 100”, the highly anticipated financial performance ranking of pharma companies headquartered in the APAC region, is coming soon. Don’t miss your opportunity to position yourself as a leader in APAC pharma with a sponsorship in this indispensable publication.  

Topic company-analysis Market Intelligence Outlook

HBW Insight : コンシューマーヘルスケア産業のニュース

Italy's Supplements Market Gets Big Boost From COVID After Solid 2019

Coronavirus pandemic drove up sales of vitamin C supplements and other immunity boosters in Italy in the opening three months of the year.

Topic Coronavirus Dietary Supplements